Lower BP target showed no clear difference in total mortality compared with standard BP target (high certainty).
It is very uncertain whether combination therapy changes total mortality compared with monotherapy (very low certainty).
It is very uncertain whether combination with potassium‐sparing diuretics changes total mortality compared with monotherapy (very low certainty).
First‐line beta‐blocker showed no clear difference in total mortality compared with placebo (moderate certainty).
First‐line calcium channel blocker showed no clear difference in total mortality compared with placebo (low certainty).
Beta‐blockers showed no clear difference in total mortality compared with renin‐angiotensin system inhibitors (moderate certainty).
Dopamine showed no clear difference in total mortalitya compared with norepinephrine (high certainty).
It is very uncertain whether terlipressin changes total mortalitya compared with norepinephrine (very low certainty).
Vasopressin showed no clear difference in total mortalitya compared with norepinephrine (moderate certainty).
It is very uncertain whether phenylephrine changes total mortalitya compared with norepinephrine (very low certainty).
Epinephrine showed no clear difference in total mortalitya compared with norepinephrine (low certainty).
It is very uncertain whether evening changes all‐cause mortality compared with morning dosing regimen (very low certainty).
CCBs showed no clear difference in all‐cause mortality compared with diuretic (moderate certainty).
CCBs showed no clear difference in all‐cause mortality compared with ACE inhibitor (low certainty).
CCBs showed no clear difference in all‐cause mortality compared with ARB (moderate certainty).
CCBs showed no clear difference in all‐cause mortality compared with β‐blocker (moderate certainty).